In this webinar, speakers discuss the role of T cell biology in cancer immunotherapy.
The cancer immunity cycle involves several sequential steps leading to an effective T cell-mediated tumor eradication. However, many steps in the cycle can be disrupted, resulting in a tumor evading the host’s immune surveillance and response. The success of immune checkpoint inhibitors like anti-PD-1 or anti-PD-L1 in activating cancer-killing T cells that were suppressed by cancer has paved the way for novel targets and therapeutics in immuno-oncology.
In this webinar, Dr. Marrit Putker, Dr. Pirouz Daftarian, and Dr. Saskia De Man focus on the impact of T cell-directed immunotherapy on the cancer-immunity cycle. Mechanisms and targets capable of modulating and enhancing T cell activity will be presented, including the application of relevant methods such as organoid models and co-cultures, and the integration of High Content Imaging (HCI).
Key Topics Include:
- Identify the right assays targeting T cell biology with immunotherapeutics at the different steps of the cancer immunity cycle such as T cell activation, migration, infiltration, and tumor killing
- Application of a unique 3D organoid platform with immune cell co-culture for immunotherapy studies and the advantages of autologous systems
- Integration of high content imaging-based screening to evaluate drug responses in 3D assays
- Modeling T cell exhaustion in a more physiologically relevant in vitro human system for the function-based screening of successful immunotherapeutics that delay or reverse this roadblock in antigen-specific T cell activity/proliferation
Click to watch the webinar recording. To view the presentation full screen simply click the square icon located in the bottom-right corner of the video-viewer.
Resources
Presenters
Scientist
Crown Bioscience
Dr. Saskia De Man performed her PhD research at the University of Amsterdam with Renée van Amerongen. Here, she used advanced imaging and gene editing techniques to study WNT/beta-catenin signalling at endogenous levels. During this time, she was also a Fulbright Scholar and joined the lab of Andres Lebensohn at the National Institutes of health for several months. Since finishing her PhD, Saskia has joined the immuno-oncology department at CrownBioscience the Netherlands, where she applies her knowledge in cell biology and advanced microscopy to help clients test their immune modulatory drugs in a relevant 3D in vitro culture system.
Director, In Vitro and R&D
Crown Bioscience
Dr. Marrit Putker (Director in vitro & R&D) received training in molecular cancer biology at Utrecht University, followed by postdoctoral studies at the MRC LMB (Cambridge, UK) and the Hubrecht Institute (Utrecht, NL). Concentrating on tumor stem cell biology and drug sensitivity, she has developed and gained expertise in state-of-the-art organoid technologies while working in the lab of Prof. Dr. Clevers. In 2020, she joined Crown Bioscience to setup and lead the novel research site in Utrecht. From this organoid-research-dedicated laboratory, she now continues to manage Crown’s in vitro R&D activities, driving collaborations with academic and industry partners around the globe.
Director, Scientific Engagement
Crown Bioscience
Dr. Pirouz Daftarian completed his PhD training in immunology in Faculty of Medicine of the University of Ottawa, in 1998. Since then, he has been leading studies on cancer immunology and autoimmunity, in academia, and biotech. He joined Crown Bioscience / JSR Life Sciences in 2017 and led the developing applications for IO products and as a Director of Scientific Engagement for models of autoimmunity and In Vitro IO. Of prior experience, pirouz was with NGM Biopharmaceutical, was a faculty at Miller School of Medicine of University of Miami and a Head Scientist, Cancer Biology, at IMV Inc. Pirouz has authored > 80 peer reviewed papers, has served as a reviewer of DOD, NIH, NCI, is a reviewer for several journals, and acted as a consultant pharma and biotech companies.
Production Partner
Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) providing discovery, preclinical, and translational platforms to advance oncology and immuno-oncology.
Additional Content From Crown Bioscience
What’s Next in Preclinical Cancer Immunotherapy Research?
This webinar will include a panel discussion of key topics in the field of cancer immunotherapy, including new and emerging methods, recent publications, and future directions.
Analyzing the Suppressive TME in in Vitro Based Assays
Experts describe suppressive tumor immune microenvironment compartments and patient-derived tissue technologies capable of recapitulating the TME for clinically-relevant studies.
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
Experts provide an overview of ex vivo and in vitro methods, techniques, and model systems for research within the cancer-immunity cycle framework.
Additional Content From Scientist.com
Circulating Nucleosome Quantification (Nu.Q®) Technology for Monitoring Target Engagement and Adverse Events in Oncology Trials
Join us for a comprehensive webinar featuring experts in epigenetics and assay development, focusing on the scientific foundations and applications of Nucleosome Quantification (Nu.Q®) Technology in the realms of drug development and disease monitoring.
Innovative Approaches to Assessing Thyroid Disruption: The 3D Human Thyroid Microtissue Model
Dr. Chad Deisenroth, PhD, from the US EPA, introduces an advanced human in vitro 3D thyroid microtissue model designed to evaluate thyroid hormone disruption, addressing current challenges with existing models.
Discover the Freshness of Frozen PBMCs – An Assessment of Cryopreservation Impact on T Cell Activation and Phenotype
Discover the impact of cryopreservation of PBMCs on T cell activation and phenotype in Lonza’s free webinar.
Related Content
The Translational Utility of Ultrasound and Photoacoustics in Head and Neck Oncology
Dr. Mukund Seshadri presents his interdisciplinary research on developing and evaluating ultrasound and photoacoustic imaging for oral oncology applications, with a focus on the prognostic utility of these methods in assessing treatment responses in head and neck cancer patients.
Assessing Antigen-Specific T-Cell Functionality with Dendritic Cell/CD8⁺ T Cell Co-culture
In this webinar, learn how to set up DC and CD8⁺ T cell co-culture experiments and assess T cell proliferation and killing activity.
A Ready-to-Analyze High-Plex Spatial Signature Development Workflow for Cancer Immunotherapy
In this webinar, Aditya Pratapa and Lorcan Sherry present a new workflow for analyzing multiplex immunoflurescence images.